Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

554 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 223
Recruiting: 123
Ph III recruiting: 12
Growth YoY: +27.5%
Industry share: 45%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (94)

clinicaltrialsPublishedShowing 101–150 of 554 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06517719	Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer	recruiting	—	500	Novartis PharmaceuticalsINDUSTRY	1	Jul 13, 2026	clinicaltrials
NCT06004661	Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function	active not recruiting	Phase 2	23	Novartis PharmaceuticalsINDUSTRY	5	Jul 10, 2026